Norethindrone

Limits on what this shows

• Key negative/null findings: The isolated-mitochondria study's own title is a negative/protective finding for classic osmotic mitochondrial swelling.
• At-risk subgroups: None established; no mammalian in vivo or human data located.

Regulatory status

No mitochondrial or energy-metabolism warning in the DailyMed label; DrugBank's full mechanism-of-action listing for norethisterone (progesterone receptor, androgen receptor, glucocorticoid receptor, ABCB1 transporter) names no mitochondrial target.

Population evidence

(1) "Differential effects of synthetic progestagens on neuron survival and estrogen neuroprotection in cultured neurons." Molecular and Cellular Endocrinology. 2014;384:52-60. PMID 24424444. In vitro cultured-neuron study testing seven progestagens, including norethindrone (NET) and norethindrone acetate (NETA), for effects on estrogen receptor expression, estrogen-induced neuroprotection against apoptosis, and BDNF expression. Medroxyprogesterone acetate blocked estrogen's neuroprotective/BDNF effects; levonorgestrel and nesterone were neuroprotective and did not block estrogen; norethindrone, norethindrone acetate, norethynodrel, and norgestimate showed variable effects without a single consistent direction reported in the abstract. (2) A study indexed as PMID 4322804, titled "Inhibition of mitochondrial swelling by 19-nor-ethynyltestosterone acetate and other steroids" (19-nor-ethynyltestosterone acetate is norethindrone acetate) — an in vitro isolated-mitochondria assay. The title itself states norethindrone acetate inhibited mitochondrial swelling, a protective/membrane-stabilizing direction; the full abstract (species, tissue, magnitude, comparator steroids) could not be retrieved in this review despite repeated attempts across PubMed, ScienceDirect, and academic search APIs (persistent HTTP 429 responses; see access notes), so only the title-stated direction is used here.

Mechanism

No single mechanism established; results point in different directions across very different assay systems (isolated mitochondria: protective; cultured neurons: mixed/inconsistent). See Overlap map for the fish-model oxidative-stress pathway evidence (ferroptosis, PI3K/AKT signaling) that is adjacent to, but not the same measurement as, mitochondrial structure/function.

Counter-evidence held on record

See Overlap map: partially shares evidence with Oxidative stress below via the fish-model pathway data. Evidence is in vitro, non-systemic, and directionally mixed. Do not present as either "protects mitochondria" or "damages mitochondria" to consumers.

Limits on what this shows

• Key negative/null findings: No human systemic oxidative-stress study isolating norethindrone or the progestin-only-pill formulation was located and opened in this review.
• At-risk subgroups: None established in humans.

Regulatory status

No oxidative-stress or antioxidant warning in the DailyMed label.

Population evidence

(1) "Norethindrone causes oxidative stress, intestinal injury, and disturbed gut microbiota composition in adult female western mosquitofish (Gambusia affinis)." Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology. 2025. PMID 40763868. Adult female mosquitofish exposed to norethindrone at 5.0, 50.0, and 500.0 ng/L (environmentally relevant waterborne concentrations, not oral clinical dosing) for 42 days: elevated reactive oxygen species, malondialdehyde, superoxide dismutase, glutathione S-transferase, and glutathione peroxidase; activation of ferroptosis and PI3K/AKT signaling pathways; intestinal histopathology (increased villus spacing, reduced epithelial height, thinner muscle layer, fewer goblet cells) and growth inhibition. (2) "The impact of co-exposure to polystyrene microplastics and norethindrone on gill histology, antioxidant capacity, reproductive system, and gut microbiota in zebrafish (Danio rerio)." Aquatic Toxicology. 2024. PMID 38968675. Title confirms antioxidant capacity was a measured endpoint; full abstract and direction could not be retrieved in this review (rate-limited; see access notes), and this is a co-exposure design, so norethindrone's independent contribution cannot be isolated from the microplastic exposure. (3) Class-level, different-drug comparator: a guinea pig long-term progestin-only-contraceptive model (Vascular Cell, 2010) using medroxyprogesterone acetate, not norethindrone, found an eight-fold elevation in 8-isoprostane and elevated 8-oxoG DNA-damage marker specifically in the combined estradiol+MPA group, localized to uterine tissue; MPA alone did not reach the same magnitude. Included as Tier C context only; a different drug and different (reproductive-tract, not systemic) tissue.

Mechanism

Not established for norethindrone in mammalian or human tissue. The fish studies establish biological plausibility that norethindrone can activate oxidative-stress pathways under some exposure conditions, at environmental (chronic, low-dose, waterborne) exposure in a non-mammalian model.

Counter-evidence held on record

See Overlap map: shares evidence with Gut microbiome risk below (same two studies) and partially with Mitochondrial burden above. This is environmental/aquatic-toxicology animal evidence only. It must not be presented to consumers as demonstrated in humans or at contraceptive dosing.

Limits on what this shows

• Key negative/null findings: A meta-analysis titled "Relevance of serum copper elevation induced by oral contraceptives" (Contraception journal) was identified but could not be opened in this review (see Sources); it is not used to support any specific magnitude here.
• At-risk subgroups: Not applicable in the depletion sense; this is an excess-direction finding for the combined-pill class, unconfirmed in magnitude for the progestin-only product.

Regulatory status

No copper warning in the DailyMed label.

Population evidence

"Effect of oral contraceptive progestins on serum copper concentration." European Journal of Clinical Nutrition (Nature Publishing). Cross-sectional epidemiologic study, West Germany, 1987-1988, n=610 nonpregnant, nonlactating women aged 18-44. All combined-pill users showed elevated serum copper versus non-users; increase varied by progestin: antiandrogen progestins +55%, desogestrel +46%, norethisterone/lynestrenol (grouped, not isolated) +42%, levonorgestrel +34%. Authors noted serum copper "varied more strongly by different progestin compounds than by estrogen contents," but all subjects in this study used combined (estrogen-containing) pills; no estrogen-free arm existed.

Mechanism

Hormonal disturbance (mechanism class F): estrogen-driven increase in hepatic ceruloplasmin synthesis is the classically established driver of OC-associated hypercupremia, similar to pregnancy-associated elevation; this study's finding that magnitude varies by progestin suggests a modulating, not purely estrogen-independent, progestin contribution. Because norethindrone POP has no estrogen partner, and its label separately documents SHBG decreasing (the opposite of the SHBG increase typical of estrogen exposure), the isolated progestin-only contribution to hepatic protein synthesis, and therefore to any copper rise, is mechanistically uncertain and plausibly smaller.

Counter-evidence held on record

Norethisterone was grouped with lynestrenol in the source study, not isolated; all subjects used a combined (estrogen-containing) pill, not the progestin-only product. This is an excess/retention-direction finding, not a deficiency. Do not use this entry to justify copper supplementation for norethindrone users; supplementation would run the wrong direction and could compound an existing mild excess.

Limits on what this shows

• Key negative/null findings: Per Hard Rule 2, anemia as diagnosed in the two large population studies is a clinical outcome (hemoglobin-threshold-based), not a direct measurement of iron stores; where ferritin/serum iron were the actual measured parameter (the classic literature cited by the narrative review, including a 1985 American Journal of Clinical Nutrition paper, PMID 3984924), this review located the citation but could not open the full text to confirm magnitude (see Sources) and does not assert specific figures from it.
• At-risk subgroups: Progestin-only-pill users with continued irregular or breakthrough bleeding — a recognized pattern with norethindrone specifically, given its short half-life and strict-timing dependence — may not realize the iron-sparing benefit seen in amenorrheic users; this subgroup was not separately quantified in any source opened in this review.

Regulatory status

No iron warning or interaction in the DailyMed label; menstrual irregularity is documented as the most common adverse reaction, without a uniform direction stated.

Population evidence

(1) Cross-sectional analysis of 46 Demographic and Health Surveys, 2008-2023, n=790,065 non-pregnant women aged 15-49 across four global regions (PLOS ONE): adjusted odds ratio for anemia with oral contraceptive pill use 0.60 (95% CI 0.49-0.72) versus non-use; injectables 0.37 (0.30-0.45); implants 0.57 (0.44-0.73). "Oral contraceptive pills" was not broken out by specific progestin. (2) Finnish nationwide nested case-control study (European Journal of Epidemiology, 2025), 3,100 anemia cases matched to 13,143 controls from a base of 588,712 women: progestin-only pills (general category) adjusted odds ratio 0.42 (95% CI 0.35-0.51); desogestrel-only specifically 0.40 (0.32-0.48), the only individually named POP progestin — Finland's POP market is desogestrel-dominated, and norethindrone was not separately reported. (3) A narrative review (Journal of Blood Medicine, "Hematological Profile Changes Among Oral Contraceptive Users") states "most oral contraceptive users had higher hemoglobin, platelet, and erythrocyte counts than non-users" and "serum iron levels have been shown to be higher among OC users," citing reduced menstrual bleeding volume and possible enhanced intestinal absorption as mechanisms; norethindrone was not specifically named in this review.

Mechanism

Hormonal/dilutional disturbance (mechanism class F): reduced or altered menstrual blood loss during progestin-only pill use (ranging from lighter flow to amenorrhea in a subset of users) preserving iron stores.

Counter-evidence held on record

See Overlap map: this entry shares its underlying evidence and mechanism with Oxygen delivery/utilization below. This is a protective, reverse-direction finding, not a deficiency risk. Do not use it to argue against iron-status monitoring in symptomatic patients or those with continued heavy or irregular bleeding. Norethindrone was not isolated as the studied progestin in the largest datasets; this is class-level extrapolation.

Limits on what this shows

• Key negative/null findings: The Massachusetts General Hospital n=10 pilot is a genuine null result for the primary diversity/composition outcome, directly counter to the animal-model disruption signal; recorded here as required counter-evidence, with the caveat that it is small (n=10) and does not specify which contraceptive formulation was used.
• At-risk subgroups: None established in humans.

Regulatory status

No microbiome-related warning in the DailyMed label.

Population evidence

(1) Mosquitofish study (PMID 40763868, above): "NET exposure significantly altered the structure and function of the microbial community within the GI tract" per 16S rRNA sequencing, alongside intestinal histopathological injury; environmental exposure, not oral dosing. (2) Zebrafish co-exposure study (PMID 38968675, above): gut microbiota named as a measured endpoint; direction and magnitude not retrieved in this review (rate-limited). (3) Human pilot study (Massachusetts General Hospital, longitudinal design, n=10 healthy women aged 16-40, blood and stool at baseline, 1 month, and 6 months after oral contraceptive initiation; specific formulation/progestin not stated in the source): "no changes were noted in the diversity or composition of the gut microbiome within six months after OC initiation," though functional shifts in peptidoglycan and amino-acid biosynthesis pathway abundance were observed. (4) Two further human studies were identified by title only and not opened in this review: "Gut Microbiota Shifts with Lifetime Duration of Oral Contraception Use" (2025) and a pilot study on hormonal-birth-control-associated altered gut microbiota beta-diversity in physically active females (Journal of Applied Physiology, 2025); neither is drug-specific to norethindrone and neither is used to support this grade.

Mechanism

Not established for norethindrone in humans; microbiome disruption (mechanism class G) is directionally supported only by the non-mammalian, environmental-exposure animal data.

Counter-evidence held on record

See Overlap map: shares evidence with Oxidative stress above (same two fish studies). Evidence is genuinely conflicting across model systems and the human sample size located is tiny. Do not present as an established human effect of oral norethindrone.

Limits on what this shows

• Key negative/null findings: Per Hard Rule 2, "anemia" as diagnosed in the two large population studies (hemoglobin-threshold-based) is an appropriate direct endpoint for this specific category, since hemoglobin and hematocrit are the named parameters, unlike the Iron entry where anemia-as-outcome required more careful framing against iron stores specifically.
• At-risk subgroups: Same caveat as Iron: progestin-only-pill users with continued irregular or breakthrough bleeding may not realize this population-level benefit.

Regulatory status

No hematologic warning in the DailyMed label beyond general precautions; hemoglobin/hematocrit are not addressed.

Population evidence

Same three sources as the Iron entry above: the 46-country DHS analysis (oral pills, adjusted OR for anemia 0.60, 95% CI 0.49-0.72, n=790,065), the Finnish nested case-control study (progestin-only pills, adjusted OR 0.42, 95% CI 0.35-0.51, from a base of 588,712 women), and the narrative review reporting "higher hemoglobin, platelet, and erythrocyte counts" and higher hematocrit/packed-cell volume among oral contraceptive users generally, citing a classic 1967 study. See Overlap map: this entry and Iron rest on the same underlying source set and mechanism; it is written here specifically in terms of hemoglobin, hematocrit, and anemia risk — the parameters this category explicitly names — rather than iron stores.

Mechanism

Hormonal/dilutional disturbance (mechanism class F): reduced or altered menstrual blood loss preserving red-cell mass and hemoglobin; the same mechanism proposed for the Iron entry.

Counter-evidence held on record

See Overlap map: this entry and Iron are not independent confirmations of each other; both rest on the same underlying source set. This is a protective, reverse-direction finding. Do not present as license to skip hematologic monitoring in symptomatic or heavily-bleeding patients. Class-level; norethindrone not isolated in the largest datasets.

Limits on what this shows

• Why no grade: Both conditions for ungraded were met. (1) No Tier B or C evidence: this review searched via WebSearch (multiple phrasings, including "norethindrone ATP synthase inhibition," "norethisterone mitochondrial respiration ATP synthesis," "norethindrone ATP cellular energy metabolism liver," and "progestogen norethisterone electron transport chain complex activity," among others, before this session's search-tool budget was exhausted) and via direct fetches against PubMed's search-listing pages, the Europe PMC REST API (separately queried for "ATP production," "ATP synthesis," and "mitochondrial respiration," each combined with norethindrone/norethisterone), the Semantic Scholar API, and DrugBank's full mechanism-of-action page (which lists progesterone-receptor, androgen-receptor, glucocorticoid-receptor, and ABCB1-transporter targets, and nothing energy-metabolism-related) — none returned an on-topic result. (2) No circulating claim to rebut: consumer material on "does birth control make you tired" was located, but it attributes fatigue to progesterone's sedative, GABA-A-potentiating central nervous system pharmacology — the drug's own recognized mechanism, not a nutrient- or ATP-depletion claim — so there is no distinct ATP-production claim in circulation to grade white. Tooling note: several Europe PMC and PubMed queries specific to this category returned HTTP 429 rate-limit responses during this session even after repeated waits (45-120 seconds) and query rephrasing; this is disclosed so a future reviewer can distinguish a possible residual tooling gap from a confirmed literature gap, but the number and diversity of attempts made meets this protocol's thoroughness bar before assigning ungraded.